Nature Communications (Jun 2016)

Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy

  • Ke-Qiong Deng,
  • Aibing Wang,
  • Yan-Xiao Ji,
  • Xiao-Jing Zhang,
  • Jing Fang,
  • Yan Zhang,
  • Peng Zhang,
  • Xi Jiang,
  • Lu Gao,
  • Xue-Yong Zhu,
  • Yichao Zhao,
  • Lingchen Gao,
  • Qinglin Yang,
  • Xue-Hai Zhu,
  • Xiang Wei,
  • Jun Pu,
  • Hongliang Li

DOI
https://doi.org/10.1038/ncomms11432
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 21

Abstract

Read online

Abstract Although pathological cardiac hypertrophy represents a leading cause of morbidity and mortality worldwide, our understanding of the molecular mechanisms underlying this disease is still poor. Here, we demonstrate that suppressor of IKKɛ (SIKE), a negative regulator of the interferon pathway, attenuates pathological cardiac hypertrophy in rodents and non-human primates in a TANK-binding kinase 1 (TBK1)/AKT-dependent manner. Sike-deficient mice develop cardiac hypertrophy and heart failure, whereas Sike-overexpressing transgenic (Sike-TG) mice are protected from hypertrophic stimuli. Mechanistically, SIKE directly interacts with TBK1 to inhibit the TBK1-AKT signalling pathway, thereby achieving its anti-hypertrophic action. The suppression of cardiac remodelling by SIKE is further validated in rats and monkeys. Collectively, these findings identify SIKE as a negative regulator of cardiac remodelling in multiple animal species due to its inhibitory regulation of the TBK1/AKT axis, suggesting that SIKE may represent a therapeutic target for the treatment of cardiac hypertrophy and heart failure.